Bladder cancer is diagnosed in 55,000 - 60,000 individuals annually in the United States. Patients whose cancer has spread to deeper tissues in the bladder and/or nearby lymph nodes may be treated with a radical cystectomy, the surgical removal of the bladder and nearby lymph nodes.

This approach may be able to cure the patient, however recurrences do occur. Researchers want to find out which patients may be more susceptible to a recurrence so that they can either monitor them more closely or treat them more aggressively to reduce the risk of recurrence.

An article was published in Lancet Oncology saying that markers may help predict the risk of cancer recurrences in patients who are treated with a radical cystectomy. Researchers from Texas and Canada conducted a clinical study to evaluate markers found in the the tissue samples taken after surgery. The markers tested included the expression of Bcl-2, caspase-3, P53, and survivin.

The study found that those patients that had an altered expression of Bcl-2, caspase-3, P533 and survivin were associated with over four times the risk of cancer recurrence. Also, the altered expression of all of these bio-markers was associated with nearly seven times the risk of death from cancer.

The researchers conclude that these findings support other studies that show these bio-markers can help predict who will remain cancer free. They look at this as moving forward towards more individualized treatments for the patients.

It did not say in the article whether using this test after the surgery would help them to determine if chemotherapy or radiation would be something that could reduce the risk of recurrence if the markers would show a high risk category of recurrence. I think this these studies are great but we need to be moving forward to get the patients to benefit from this vital information.